Notizie AIOM – anno XVII
FDA Pipeline: Designations for Treatments of Graft-vs-Host-Disease, Colorectal Cancer, Pancreatic Cancer, and More
January 11, 2019 - The FDA’s Fast Track program is designed to facilitate the development of new treatments for serious or life-threatening conditions for which there is a significant unmet medical need. A therapeutic agent that receives Fast Track designation can ...Leggi tutto
Statement from American Society of Clinical Oncology (ASCO) President Monica M. Bertagnolli, MD, FACS, FASCO, on the American Cancer Society Cancer Facts and Figures 2019 Report
January 9, 2019 - “This year’s Facts and Figures report provides both encouraging and concerning news on the delivery and impact of cancer care across the United States. Although we continue to see a significant decline in the overall cancer death rate, the report ...Leggi tutto
The association of socioeconomic status with quality of life in cancer patients over a 6-month period using individual growth models
Studies examining longitudinal associations between socioeconomic factors and quality of life (QoL) in cancer patients are rare. This study investigates changes in QoL over a 6-month period. Four hundred forty-two cancer patients (mean age 64, SD = 11, 70% male) ...Leggi tutto
Cancer Statistics, 2019
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data, available through 2015, were collected by the ...Leggi tutto
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
Radium-223, a targeted alpha therapy, is used to treat symptomatic patients with castration-resistant prostate cancer (CRPC) and bone metastases. Data for radium-223 in asymptomatic CRPC patients with bone metastases are lacking. This was a prospective, single-arm phase ...Leggi tutto
Association between age and sex and mortality after adjuvant therapy for renal cancer
In phase 3 trials of patients with resected high-risk renal cell carcinoma, adjuvant sunitinib has demonstrated no overall survival (OS) benefit, an uncertain disease-free survival (DFS) benefit, and increased toxicity versus placebo. To identify patients who may derive ...Leggi tutto
Scheda informativa condivisa da ISS, PMA, AIMAC e AIOM
Suggerimenti semplici su come preservare la fertilità prima dei trattamenti antitumorali, firmate da Istituto Superiore di Sanità (ISS), Registro Nazionale di Procreazione Medicalmente Assistita (PMA), Associazione Italiana Malati di Cancro, parenti e amici ...Leggi tutto
Dal Soroptimist International Club Genova a favore delle ragazze STEM
Il Premio, del valore di 2.000 Euro, sarà attribuito ad una Tesi di Laurea Magistrale in campo Emato-Oncologico, discussa da una studentessa dell’Università degli Studi di Genova negli anni accademici 2016-17 o 2017-18, in una delle seguenti discipline: ...Leggi tutto